Table 3.

IL6 association with breast cancer in the 4-Corner's Study

IL6 marker*Race/ethnicityGenotypePremenopausal
Postmenopausal
Cases, n (%)Controls, n (%)OR (95% CI)Recent estrogen
No recent estrogen
Cases, n (%)Controls, n (%)OR (95% CI)Cases, n (%)Controls, n (%)OR (95% CI)
rs1800797NHWAA150 (36.5)127 (30.8)1.00195 (37.0)190 (31.9)1.0091 (41.7)106 (34.3)1.00
(−596A>G)AG/GG261 (63.5)285 (69.2)0.77 (0.57-1.04)332 (63.0)405 (68.1)0.80 (0.63-1.03)127 (58.3)203 (65.7)0.69 (0.48-1.00)
H/NAAA160 (67.5)175 (66.0)1.00139 (66.2)176 (64.9)1.0093 (76.2)112 (61.5)1.00
AG/GG77 (32.5)90 (34.0)0.98 (0.66-1.44)71 (33.8)95 (35.1)0.91 (0.62-1.35)29 (23.8)70 (38.5)0.48 (0.28-0.83)
rs1800796NHWGG356 (85.8)372 (90.1)1.00469 (88.3)536 (89.6)1.00189 (86.3)273 (87.8)1.00
(−572G>C)GC/CC59 (14.2)41 (9.9)1.53 (0.99-2.37)62 (11.7)62 (10.4)1.12 (0.77-1.64)30 (13.7)38 (12.2)1.33 (0.78-2.26)
H/NAGG135 (56.7)154 (58.3)1.00120 (57.4)145 (53.1)1.0076 (62.3)105 (57.4)1.00
GC/CC103 (43.3)110 (41.7)1.09 (0.75-1.58)89 (42.6)128 (46.9)0.84 (0.58-1.22)46 (37.7)78 (42.6)0.77 (0.47-1.28)
rs1800795NHWGG149 (36.2)123 (29.8)1.00190 (35.8)180 (30.1)1.0088 (40.2)102 (32.8)1.00
(−174G>C)GC/CC263 (63.8)290 (70.2)0.76 (0.56-1.02)340 (64.2)418 (69.9)0.78 (0.61-1.00)13 (159.8)20 (967.2)0.68 (0.47-0.99)
H/NAGG159 (66.8)173 (65.3)1.00135 (64.6)173 (63.6)1.0092 (75.4)109 (59.6)1.00
GC/CC79 (33.2)92 (34.7)0.97 (0.66-1.42)74 (35.4)99 (36.4)0.93 (0.63-1.37)30 (24.6)74 (40.4)0.44 (0.26-0.77)
rs2069832,NHWGG147 (35.8)121 (29.5)1.00190 (35.9)179 (29.9)1.0086 (39.4)102 (33.0)1.00
G>AGA/AA264 (64.2)289 (70.5)0.76 (0.56-1.03)339 (64.1)419 (70.1)0.77 (0.60-1.00)132 (60.6)207 (67.0)0.70 (0.48-1.02)
intronH/NAGG157 (66.0)172 (64.9)1.00132 (63.5)172 (63.2)1.0092 (76.0)108 (59.0)1.00
GA/AA81 (34.0)93 (35.1)0.98 (0.67-1.44)76 (36.5)100 (36.8)0.96 (0.65-1.41)29 (24.0)75 (41.0)0.43 (0.25-0.74)
rs2069849,NHWCC390 (94.4)396 (96.1)1.00507 (95.5)566 (94.6)1.00213 (97.3)300 (96.8)1.00
Exon 5CT/TT23 (5.6)16 (3.9)1.35 (0.70-2.63)24 (4.5)32 (5.4)0.83 (0.48-1.44)6 (2.7)10 (3.2)0.94 (0.33-2.70)
C>TH/NACC214 (89.9)229 (86.4)1.00185 (88.1)237 (87.5)1.00112 (91.8)161 (88.0)1.00
CT/TT24 (10.1)36 (13.6)0.68 (0.39-1.20)25 (11.9)34 (12.5)0.94 (0.53-1.67)10 (8.2)22 (12.0)0.62 (0.27-1.43)
Haplotype,§
NHWAGGGC(48.9)(47.3)1.06 (0.87-1.30)(50.7)(47.4)1.15 (0.97-1.35)(53.1)(49.1)1.19 (0.93-1.54)
GGCAC(39.0)(44.1)0.83 (0.68-1.01)(39.0)(42.5)0.87 (0.74-1.04)(36.2)(41.9)0.77 (0.59-0.99)
ACGGC(6.8)(5.0)1.48 (0.97-2.27)(5.9)(4.8)1.20 (0.84-1.74)(6.8)(6.3)1.21 (0.72-2.02)
AGGGT(2.9)(1.7)1.45 (0.72-2.91)(1.3)(2.5)0.80 (0.46-1.42)(1.3)(1.5)1.03 (0.35-3.05)
H/NAAGGGC(50.8)(49.6)1.01 (0.79-1.29)(48.5)(45.0)1.15 (0.88-1.49)(59.1)(48.4)1.55 (1.09-2.19)
GGCAC(18.5)(19.1)1.02 (0.74-1.41)(20.0)(18.9)1.12 (0.81-1.56)(13.6)(19.9)0.70 (0.44-1.11)
ACGGC(25.0)(23.6)1.12 (0.83-1.49)(24.5)(28.3)0.85 (0.63-1.13)(22.3)(23.2)0.92 (0.61-1.39)
AGGGT(5.0)(6.8)0.66 (0.37-1.15)(5.8)(6.7)0.83 (0.48-1.44)(4.1)(6.0)0.57 (0.25-1.30)
  • NOTE: ORs and 95% CIs adjusted for age, study center, referent year BMI, lifetime physical activity score, parity, and percentage Native American ancestry.

    Abbreviations: NHW, Non-Hispanic white; H/NA, Hispanic/Native American.

  • * IL6 gene region: rs1800797, rs1800796, and rs1800795, 5′ promoter; rs2069832, intron + 180 of exon 2; rs2069849, coding exon 5.

  • Referent genotype is homozygous wild-type for the major allele in our study population (dominant inheritance model).

  • Allele designation for markers in order: rs1800797, rs1800796, rs1800795, rs2069832, and rs2069849.

  • § Haplotype dose based on probability of carrying the haplotype (from 0 to 2 copies), estimated from controls, as a continuous variable; risk of carrying one copy versus not carrying the haplotype for the four most common haplotypes.